Abstract visualization of a brain hemorrhage from an MRI perspective, with vivid colors marking the hemorrhagic areas against the brain's grayscale anatomy.
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Alterity Therapeutics Ltd (ASX:ATH) has reported positive interim results from its Phase 2 clinical trial assessing the treatment of patients with neurodegenerative condition multiple system atrophy (or MSA) with drug ATH434.

The trial involves 10 participants, and the interim results relate to 7 who have been treated with ATH434 over a six-month period, with 3 of these also completing 12 months of treatment.

Reduced disability related to activities of daily living was observed among 43% of participants, assessed in this way through the unified MSA rating scale (or UMSARS) after six months of treatment.

During the same period, 29% were assessed by both the treating physician and patient as having stable or improved neurological symptoms, and were noted as ‘clinical responders’.

Importantly, the clinical responders on average had reduced accumulation of iron in the substantia nigra, putamen and globus pallidus – as seen on the MRI – as well as stable levels of NFL, a marker of axonal injury, when compared to participants who declined.

This suggests ATH434’s efficacy in reducing α-synuclein pathology and preserving neuronal function by restoring normal iron balance in the brain.

Alterity CEO Dr David Stamler said he was encouraged by the positive data.

“As MSA is a rapidly progressive and unremitting disease, we expected to see decline in all participants,” he said.

“Instead, we saw favorable clinical and biomarker outcomes in some patients suggesting that ATH434 has the potential to modify the course of this devastating condition.

“We were also very pleased to see that the clinical responders had biomarker evidence of stable disease as this provides an objective indication of potential efficacy.”

The price of Alterity shares rose on the news. At 11:37 AEDT, they were trading at 0.6 cents, a rise of 20% since the market opened.

ATH by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Index approaches record high as Austal spikes on US Navy contract | September 16, 2024

The ASX200 closed up a 0.27% at 8,121 points, as the market came within a whisker…
The Market Online Video

ASX Market Update: Aussie Index on the cusp of record as Real Estate stocks take the lead | September 16, 2024

The ASX200 has been up around point four six of a percent at 8,137 points. The…
America uncertainty concept

Rate cuts, assassination attempts, gold, oil, AI – what to watch in USA this week

At the time of writing this article – 12pm Sydney time on Monday – US futures…
Image of a nugget of gold

Flynn finds multiple veins of gold through diamond drilling in Tasmania

Flynn Gold Ltd has progressed diamond drilling across the Trafalgar North zone at its Golden Ridge…